12.25
Korro Bio Inc stock is traded at $12.25, with a volume of 169.77K.
It is down -0.24% in the last 24 hours and up +10.86% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$12.28
Open:
$11.86
24h Volume:
169.77K
Relative Volume:
0.96
Market Cap:
$176.68M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.9815
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-15.87%
1M Performance:
+10.86%
6M Performance:
+39.52%
1Y Performance:
-11.42%
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KRRO
Korro Bio Inc
|
12.25 | 177.11M | 6.39M | -117.26M | -79.08M | -12.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Form 4 Korro Bio Inc For: 17 July By Investing.com - Investing.com Nigeria
Korro Bio, Inc. (KRRO) awards 7,500 RSUs to Chief Operating Officer - Stock Titan
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Price to earnings forward of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Price to sales forward of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio, Inc. (KRRO) upgraded to buy: What does it mean for the stock? - MSN
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
KRRO Q1 2026 Earnings: EPS Beat Driven by Cost Control and Clinical ProgressRevenue Report - dars.gov.et
Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus - Kavout | AI
Korro Bio director Formela sells $1.54m in shares - Investing.com
Korro Bio director Formela sells $1.54m in shares By Investing.com - Investing.com South Africa
Form 4 Korro Bio Inc For: 7 July By Investing.com - Investing.com Canada
Price to book forward of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Form 144 Korro Bio For: 6 July By Investing.com - Investing.com Canada
Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock? - MSN
KRRO Q1 2026 Earnings: EPS Surpasses Estimates Amid Ongoing Clinical ProgressSlow Growth Warning - dars.gov.et
KRROKorro Bio Inc Options - Finviz
Form 144 Korro Bio For: 2 July By Investing.com - Investing.com India
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO) - TradingView
KRRO Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Korro Bio Inc For: 24 June By Investing.com - Investing.com Nigeria
Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing - marketscreener.com
Korro Bio director Jean Francois Formela sells $2.45m in shares - Investing.com UK
Korro Bio (KRRO) director-affiliated Atlas funds sell 171K shares under 10b5-1 plan - Stock Titan
Form 144 Korro Bio For: 24 June By Investing.com - Investing.com India
Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries - Stock Titan
Atlas Venture sells KRRO common stock in late May–June 2026 (KRRO) - Stock Titan
Korro Bio (KRRO) Notches Modest Gain as Shares Consolidate Near Key ResistanceGap Down Bounce Plays - dars.gov.et
Form 144 Korro Bio For: 23 June By Investing.com - Investing.com South Africa
KRRO (NASDAQ: KRRO) selling holders report recent share sales - Stock Titan
Korro Bio Inc. (KRRO) Edges Lower Amid Consolidation PhaseUnusual Call Volume - dars.gov.et
Form 144 Korro Bio For: 22 June By Investing.com - Investing.com Australia
Atlas Venture sells KRRO (KRRO) stock — 2,441 and 419 shares reported - Stock Titan
KRRO proposes sale of 3,661 shares on Nasdaq (NASDAQ: KRRO); Atlas Venture recent disposals - Stock Titan
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Korro Bio COO Chappell sells $34,309 in company stock By Investing.com - Investing.com India
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Director |
Jul 06 '26 |
Sale |
13.96 |
9,323 |
130,149 |
146,305 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):